Searching News Database: PTC Therapeutics
HSMN NewsFeed - 27 Nov 2024
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
HSMN NewsFeed - 17 May 2023
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
HSMN NewsFeed - 17 Nov 2022
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
HSMN NewsFeed - 20 May 2022
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
HSMN NewsFeed - 23 Jun 2021
Evrysdi(TM) Approved in Japan for the Treatment of Spinal Muscular Atrophy
Evrysdi(TM) Approved in Japan for the Treatment of Spinal Muscular Atrophy
HSMN NewsFeed - 30 Mar 2021
PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy
PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy
HSMN NewsFeed - 4 Dec 2020
PTC Announces Translarna(TM) Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
PTC Announces Translarna(TM) Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
HSMN NewsFeed - 12 Nov 2020
Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
HSMN NewsFeed - 1 Jun 2020
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
HSMN NewsFeed - 1 Oct 2018
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
HSMN NewsFeed - 20 Sep 2018
BlueRock Therapeutics Appoints Shane Kovacs as Chief Business and Financial Officer
BlueRock Therapeutics Appoints Shane Kovacs as Chief Business and Financial Officer
HSMN NewsFeed - 23 Feb 2016
PTC Receives Refuse to File Letter from FDA for Translarna(TM) (ataluren)
PTC Receives Refuse to File Letter from FDA for Translarna(TM) (ataluren)
HSMN NewsFeed - 8 Apr 2015
PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
HSMN NewsFeed - 13 Aug 2014
Inotek Pharmaceuticals Names David P. Southwell as President and Chief Executive Officer
Inotek Pharmaceuticals Names David P. Southwell as President and Chief Executive Officer
HSMN NewsFeed - 28 Sep 2012
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
HSMN NewsFeed - 29 Jul 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
HSMN NewsFeed - 9 Mar 2010
Human Genome Sciences Appoints David P. Southwell Executive Vice President and Chief Financial Officer
Human Genome Sciences Appoints David P. Southwell Executive Vice President and Chief Financial Officer
HSMN NewsFeed - 7 Oct 2009
Epizyme Closes $32 Million Series B Financing, Led by New Investor Bay City Capital
Epizyme Closes $32 Million Series B Financing, Led by New Investor Bay City Capital
HSMN NewsFeed - 10 Sep 2009
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
HSMN NewsFeed - 18 Aug 2009
Kolltan Pharmaceuticals Expands Board of Directors and Senior Executive Team
Kolltan Pharmaceuticals Expands Board of Directors and Senior Executive Team
HSMN NewsFeed - 1 Jun 2009
PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations
PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations
HSMN NewsFeed - 13 May 2009
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
HSMN NewsFeed - 13 Sep 2007
PTC Therapeutics Announces $20 Million Strategic Investment From Celgene Corporation
PTC Therapeutics Announces $20 Million Strategic Investment From Celgene Corporation
HSMN NewsFeed - 2 Aug 2007
PTC Therapeutics Appoints Theresa Natalicchio as Senior Vice President of Marketing and Sales
PTC Therapeutics Appoints Theresa Natalicchio as Senior Vice President of Marketing and Sales
HSMN NewsFeed - 2 May 2007
PTC Therapeutics Announces Promotion of Neil Almstead to Senior Vice President of Chemistry and CMC
PTC Therapeutics Announces Promotion of Neil Almstead to Senior Vice President of Chemistry and CMC
HSMN NewsFeed - 2 Feb 2007
Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
HSMN NewsFeed - 3 Nov 2006
PTC Therapeutics Announces Positive Phase 2 Results For PTC124 in Cystic Fibrosis
PTC Therapeutics Announces Positive Phase 2 Results For PTC124 in Cystic Fibrosis
HSMN NewsFeed - 21 Oct 2006
PTC Therapeutics Announces Encouraging Preliminary Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
PTC Therapeutics Announces Encouraging Preliminary Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Additional items found! 17
Members Archive contains
17 additional stories matching:
PTC Therapeutics
(Password required)
PTC Therapeutics
(Password required)
